Moderna Swings to $162M Profit as Q3 Revenue Hits $1.31B, Crushing Estimates
Moderna reported third-quarter 2026 revenue of $1.31 billion, up 29% year over year and far above the $885.1 million consensus, swinging to a $162 million profit, or $0.38 per share, and raised full-year revenue growth guidance to 15% to 25%.
- 01THE PRINT — Moderna reported third-quarter 2026 revenue of $1.31 billion, up 29% year over year and well above the $885.1 million consensus, swinging to a $162 million profit.
- 02THE DRIVER — International COVID vaccine sales and government partnerships drove the beat, while R&D fell 27% and the cash outlook rose by roughly $3.5 billion.
- 03THE WATCHPOINT — Whether regulators accept the intismeran Phase 3 data on a timeline that supports a 2027 launch, and whether mFLUSIVA converts into contracted flu-season volume.
WHAT HAPPENEDWhat Happened
Moderna reported third-quarter 2026 revenue of $1.31 billion on November 6, 2026, up 29% year over year, far above the $885.1 million analysts expected, according to LSEG data cited by Reuters. Net income was $162 million, or $0.38 per diluted share, against a net loss of $200 million, or $0.51 per share, a year earlier. Analysts had expected a loss of $1.25 per share. Shares rose more than 6% in premarket trading.
The beat was driven by the established vaccine business, not the pipeline. Revenue was $780 million in the United States and $533 million internationally, with higher COVID vaccine sales abroad supported by deliveries under long-term government partnerships, including agreements with the United Kingdom, Canada and Australia. Cost discipline helped the bottom line: research and development spending fell 27% year over year to $583 million as late-stage infectious-disease studies wound down.
Moderna raised its full-year 2026 revenue growth outlook to 15% to 25%, from up to 10% previously, and now expects year-end cash and investments of $8.1 billion to $8.3 billion, up from $4.7 billion to $5.2 billion. Cash stood at $8.0 billion on September 30, boosted by $2.6 billion in net proceeds from a convertible notes offering completed in September. The company expects about half of 2026 revenue to come from international markets.
The pipeline story advanced alongside the print. The FDA approved mFLUSIVA, Moderna's seasonal flu vaccine, in August, its fifth approved product globally, with a limited U.S. launch for the 2026-27 season. In October, Moderna and Merck presented positive Phase 3 results for intismeran autogene combined with Keytruda in resected high-risk melanoma: a 42% lower risk of recurrence or death, and a 58% lower risk after six months on the immunization regimen. The companies are working toward regulatory submissions and preparing for a potential commercial launch in 2027, subject to approval. The norovirus vaccine's Phase 3 interim analysis did not meet the criteria for early success, and Moderna will not start an additional cohort this season.
WHY IT MATTERSThe beat is real, but the driver is the old business
The scale of the surprise, $1.31 billion against an $885 million consensus, reflects international COVID vaccine deliveries and government partnerships, not a new product ramp. mFLUSIVA was approved after the annual contracting cycle, so its revenue contribution waits until 2027, and the cancer vaccine is still pre-commercial. The quarter proves the legacy franchise can still fund the company, not that diversification has arrived.
What changed structurally is the cost base. R&D down 27% and a $362 million year-over-year swing in net income show a company that has stopped burning at the old rate. The raised cash outlook, $8.1 billion to $8.3 billion against a prior $4.7 billion to $5.2 billion, is the concrete form of that discipline, and it buys time for the pipeline to convert.
WHY IT MATTERSThe cancer vaccine is the number the market is actually pricing
Moderna shares have risen more than eightfold this year, mostly after the intismeran trial success announced in August, according to Reuters. The market is valuing a personalized cancer vaccine that cut the risk of melanoma recurrence or death by 42%, and by 58% after six months of the regimen, before a single commercial sale exists. That makes the regulatory submissions, not the quarterly revenue, the decisive event.
The watchpoint is execution risk on two fronts: whether the FDA and European regulators accept the Phase 3 data on the timeline Moderna implies for a 2027 launch, and whether the flu vaccine's limited launch converts into contracted volume for the 2027-28 season. The earnings call at 8:00 a.m. ET will be graded on both.
SIGNAL JUDGMENT — ANALYSISA legacy franchise funding a pipeline the market has already priced
Tokenta Signal's judgment: the $1.31 billion print is a genuine beat, but it is the old COVID franchise and government partnerships doing the work while the flu vaccine waits for next season and the cancer vaccine waits for regulators. The durable signal is the cost reset: R&D down 27% and a cash outlook lifted by roughly $3.5 billion give Moderna a funded runway to convert intismeran's 42% risk reduction into a 2027 launch. The quarter buys time; the submissions decide whether the eightfold share rally was early or right.
WHAT REMAINS UNCERTAINWhat Remains Uncertain
EVIDENCEEvidence
Moderna's official third-quarter 2026 results were issued via ACCESS Newswire on November 6, 2026 and read in full: total revenue $1.313 billion, up 29% year over year; net income $162 million, or $0.38 per diluted share, against a net loss of $200 million a year earlier; U.S. revenue $780 million and international revenue $533 million; R&D $583 million, down 27%; cash $8.0 billion at September 30; 2026 revenue growth guidance raised to 15% to 25% from up to 10%; year-end cash outlook raised to $8.1 billion to $8.3 billion. The release confirms the August FDA approval of mFLUSIVA and the October Phase 3 intismeran results, a 42% lower risk of melanoma recurrence or death, 58% after six months. Reuters' same-day report agrees on the revenue beat against the $885.1 million LSEG consensus, the profit swing, the guidance raise and a premarket share rise of more than 6%.
PRIMARY SOURCESPrimary Sources
- Moderna: Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
https://markets.financialcontent.com/stocks/article/accwirecq-2026-11-6-moderna-reports-third-quarter-2026-financial-results-and-provides-business-updates - Reuters: Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-lifts-annual-revenue-forecast-strong-covid-vaccine-demand-overseas-2026-11-06/
RELATEDRelated Intelligence
- Oklo Posts First Revenue of $1.86M as Q3 Loss Widens to $41.7M, Liquidity Hits $3.13B
- Monster Q3 Sales Hit a Record $2.56B on International Growth, but Margins Squeeze Shares
- BILL Q1 Profit Beats, but an Accounting Change Makes Revenue Look Like a Miss
- Affirm Q1 Revenue Jumps 35% to $1.26B, but Delinquencies Push Shares Down